Qube Research & Technologies LTD Aveo Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $3.02 Million - $5.33 Million	356,347 Added 1203.51%	385,956 $5.77 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $71,777 - $94,690	10,859 Added 57.91%	29,609 $244,000
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $65,812 - $125,062	18,750 New	18,750 $123,000
Q3 2021 Nov 12, 2021	SELL	$5.12 - $6.89 $91,791 - $123,523	-17,928 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.21 - $7.45 $111,332 - $133,563	17,928 New	17,928 $118,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.